Susquehanna International Group
HBIO icon

Susquehanna International Group’s Harvard Bioscience HBIO Stock Holding History

Susquehanna International Group’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,130
Closed -$48.6K – 12727
2023
Q3 		$48.6K Buy
+1,130
New +$52.1K ﹤0.01% 11320
2023
Q1 		– Sell
-1,020
Closed -$28.3K – 12936
2022
Q4 		$28.3K Buy
+1,020
New +$25.1K ﹤0.01% 11642
2013
Q4 		– Sell
-5,131
Closed -$205K – 9108
2013
Q3 		$205K Buy
+5,131
New +$202K ﹤0.01% 7742

Other funds holding HBIO

WCM
Weber Capital Management San Francisco, California $100M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
MIM
Meros Investment Management Dallas, Texas $231M AUM 35.94% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's HBIO Position: Q1 2026 in Review

Susquehanna International Group sold out of Harvard Bioscience (HBIO) in Q1 2026, closing a stake of 13,987 shares — an estimated $93.5K sold.

Susquehanna International Group first reported a position in HBIO in Q3 2013 and held it in 22 quarters. The position peaked at $383K in Q1 2018. 36 funds tracked by Wall St. Rank hold HBIO as of Q1 2026.

  • Susquehanna International Group reported no remaining Harvard Bioscience position as of Q1 2026 after selling out during the quarter.
  • Susquehanna International Group sold 13,987 Harvard Bioscience shares in Q1 2026, an estimated $93.5K.
  • Susquehanna International Group first reported a position in Harvard Bioscience in Q3 2013 and held it in 22 quarters.
  • Susquehanna International Group's Harvard Bioscience position peaked at $383K in Q1 2018.
  • 36 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.